24小时热门版块排行榜

>论坛更新日志 (3960)
>文献求助 (408)
>虫友互识 (345)
>导师招生 (323)
>博后之家 (166)
>考博 (155)
>硕博家园 (154)
>休闲灌水 (141)
>论文投稿 (118)
>基金申请 (90)
>招聘信息布告栏 (55)
>考研 (54)
>教师之家 (52)
>公派出国 (43)
>绿色求助(高悬赏) (38)
>找工作 (37)

返回列表

当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖

kdl0721

金虫 (著名写手)

应助: 76 (初中生)
金币: 528.3
散金: 69
红花: 30
帖子: 1047
在线: 319小时
虫号: 1246356
注册: 2011-03-27
专业: 无机非金属基复合材料

[求助] 求Ibrutinib 一个Ⅲ期临床试验和试验数据、结果已有2人参与

试验名称：
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (RESONATE™

试验内容：http://www.clinicaltrials.gov/show/NCT01578707
求虫友帮忙查一下该试验过程和结果。谢谢！

回复此楼

» 猜你喜欢

1楼2014-03-28 15:27:48

已阅回复此楼关注TA 给TA发消息送TA红花 TA的回帖

tsenghw

铁虫 (初入文坛)

应助: 0 (幼儿园)
金币: 14.6
帖子: 2
在线: 57分钟
虫号: 4212699
注册: 2015-11-11
性别: GG
专业: 肿瘤化学药物治疗

【答案】应助回帖

N Engl J Med. 2014 Jul 17;371(3):213-23. doi: 10.1056/NEJMoa1400376. Epub 2014 May 31.
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreivy J, Clow F, James DF, Hillmen P; RESONATE Investigators.
Collaborators (67)

Abstract
BACKGROUND:
In patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL), a short duration of response to therapy or adverse cytogenetic abnormalities are associated with a poor outcome. We evaluated the efficacy of ibrutinib, a covalent inhibitor of Bruton's tyrosine kinase, in patients at risk for a poor outcome.

METHODS:
In this multicenter, open-label, phase 3 study, we randomly assigned 391 patients with relapsed or refractory CLL or SLL to receive daily ibrutinib or the anti-CD20 antibody ofatumumab. The primary end point was the duration of progression-free survival, with the duration of overall survival and the overall response rate as secondary end points.

RESULTS:
At a median follow-up of 9.4 months, ibrutinib significantly improved progression-free survival; the median duration was not reached in the ibrutinib group (with a rate of progression-free survival of 88% at 6 months), as compared with a median of 8.1 months in the ofatumumab group (hazard ratio for progression or death in the ibrutinib group, 0.22; P<0.001). Ibrutinib also significantly improved overall survival (hazard ratio for death, 0.43; P=0.005). At 12 months, the overall survival rate was 90% in the ibrutinib group and 81% in the ofatumumab group. The overall response rate was significantly higher in the ibrutinib group than in the ofatumumab group (42.6% vs. 4.1%, P<0.001). An additional 20% of ibrutinib-treated patients had a partial response with lymphocytosis. Similar effects were observed regardless of whether patients had a chromosome 17p13.1 deletion or resistance to purine analogues. The most frequent nonhematologic adverse events were diarrhea, fatigue, pyrexia, and nausea in the ibrutinib group and fatigue, infusion-related reactions, and cough in the ofatumumab group.

CONCLUSIONS:
Ibrutinib, as compared with ofatumumab, significantly improved progression-free survival, overall survival, and response rate among patients with previously treated CLL or SLL. (Funded by Pharmacyclics and Janssen; RESONATE ClinicalTrials.gov number, NCT01578707.).